ANTICANCER INDIVIDUAL PROTEOME-BASED TARGET CELL PREPARATION, METHOD FOR PRODUCING AND USING THIS PREPARATION FOR THERAPY OF CANCER AND OTHER MALIGNANT NEW GROWTHS Russian patent published in 2014 - IPC A61K48/00 C12N5/07 C12N5/09 G06F19/10 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology and oncology. A method provides: a) isolating postnatal tissue-specific pluripotent autologous stem cells (ASCs) and/or autologous progenitor cells (APCs) for the following proteome and complete transcriptomic analysis; b) isolating ASCs and/or APCs and/or pluripotent allogenic HLA-haploidentical stem cells (HLA-SCs) for remodelling of their proteome profile; c) isolating cancerous stem cells from patient's tumour; d) carrying out ASC and/or APC and CSC proteome analysis; e) carrying out ASC and/or APC and CSC complete transcriptomic analysis; f) recognising a protein complement each of which is found in the proteome profiles both of ASCs and/or APCs, and of CSCs; g) analysing the recognising protein complement for identifying intracellular signalling pathways in CSCs not subject to the neoplastic transformation as a result of carcinogenesis, and recognising target proteins defined as membrane acceptors of identified signalling pathways; h) analysing the complete transcriptomic profile of the CSC gene expression and confirming the preservation and functional significance of the structural components of the identified signalling pathways in CSCs; i) recognising ligand proteins able to activate the target proteins; j) carrying out a comparative analysis of the ASC and/or APC complete transcriptomic profiles to the transcriptomic profiles contained in the known data bases of transcriptomes for recognising perturbagens able to modify the gene expression profile of ASCs and/or APCs and/or HLA-SCs isolated for remodelling their proteome profile in the line of secreting the pre-recognised ligand proteins; k) remodelling the ASC and/or APC and/or HLA-SC proteome profile with perturbagens to produce the modified transcriptome profile of various cell systems able to have a regulatory influence on patient's CSCs.

EFFECT: preparation produced according to the method includes all the individual peculiarities of the patient's genome and proteome modifications, and has the regulatory influence on patient's cancerous stem cells (CSCs) and malignant cells.

8 cl, 4 dwg, 11 tbl, 4 ex